Content |
History
2025: Bankruptcy Filing
On June 30, 2025, French artificial heart manufacturer Carmat filed for bankruptcy. The corresponding application was sent to the Versailles Court of Economic Affairs.
Earlier, Carmat warned that by the end of June 2025 it could run out of money, and therefore it urgently needed additional funding in the amount of at least €3.5 million to continue its activities as usual. However, despite all efforts, it was not possible to attract this money. Therefore, the company is forced to file for insolvency. At Carmat's request, trading in its shares is suspended pending a ruling by the Court of Versailles.
In accordance with the approved Carmat business plan, the company requires €35 million to continue work over 12 months, including €20 million until the end of 2025. But there were difficulties with raising funding.
Analysts, according to Reuters, outlined the two most likely scenarios for Carmat: a takeover by a larger market participant or support from a strong financial partner willing to help the company reach profitability.
 | Given the significance of Carmat's artificial heart technology, intervention by the French state cannot be ruled out, but this seems unlikely in light of the company's obligations, the publication says. |  |
Carmat has developed an artificial heart. Aeson This device targets patients suffering from end-stage biventricular heart failure who are not available for alternative treatment. According to Carmat, the Aeson solution has high hemocompatibility, pulsation and self-regulation. The device involves the use of a portable external power supply system.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |